Letter/Communication
Reply [to: Pro-permeability Factors in Diabetic Macular Edema; The Diabetic Macular Edema Treated With Ozurdex Trial]
American journal of ophthalmology, Vol.170, p.245
10/01/2016
DOI: 10.1016/j.ajo.2016.07.014
PMID: 27561424
Abstract
[...]they state that there were no comparative data referring to the demographics and baseline ocular characteristics of patients treated with dexamethasone implant and injections of a vascular endothelial growth factor (VEGF)-neutralizing protein. [...]they question if the 2 groups were comparable, but the comparison is between 2 treatments given to the same patient population, so comparability among groups is not an issue.
Details
- Title: Subtitle
- Reply [to: Pro-permeability Factors in Diabetic Macular Edema; The Diabetic Macular Edema Treated With Ozurdex Trial]
- Creators
- Peter A CampochiaroGulnar HafizTahreem A MirAdrienne W ScottIngrid Zimmer-GallerSyed M ShahAdam S WenickChristopher J BradyIan HanLingmin HeRoomasa ChannaDavid PoonCatherine MeyerleMary Beth AronowAkrit SodhiJames T HandaSaleema KheraniYong HanRaafay SophieGuohua WangJiang Qian
- Resource Type
- Letter/Communication
- Publication Details
- American journal of ophthalmology, Vol.170, p.245
- Publisher
- Elsevier Limited; Chicago
- DOI
- 10.1016/j.ajo.2016.07.014
- PMID
- 27561424
- ISSN
- 0002-9394
- eISSN
- 1879-1891
- Language
- English
- Date published
- 10/01/2016
- Academic Unit
- Ophthalmology and Visual Sciences
- Record Identifier
- 9983979965102771
Metrics
22 Record Views